Sarepta Names AbbVie Veteran Michael Severino as CEO
Event summary
- Michael Severino, M.D., former CEO of Tessera Therapeutics and Vice Chairman at AbbVie, appointed as Sarepta's new CEO effective July 28, 2026.
- Severino succeeds Doug Ingram, who retires but will serve in an advisory role until the end of 2026.
- Severino brings over 25 years of biopharmaceutical experience, with a focus on precision medicine and rare diseases.
The big picture
Sarepta's appointment of Michael Severino as CEO signals a strategic shift towards leveraging his extensive experience in precision medicine and rare diseases. His background at AbbVie, where he oversaw significant pipeline expansion and built leading franchises in multiple therapeutic areas, suggests a focus on scaling Sarepta's capabilities. The transition also highlights the importance of maintaining momentum in Sarepta's core Duchenne muscular dystrophy programs while exploring new opportunities.
What we're watching
- Strategic Vision
- How Severino's experience in precision medicine and rare diseases will shape Sarepta's long-term strategy.
- Pipeline Expansion
- Whether Severino can accelerate the development of Sarepta's siRNA pipeline programs and other innovative therapies.
- Market Positioning
- The pace at which Sarepta can expand its reach beyond Duchenne muscular dystrophy into other therapeutic areas under new leadership.